A study in Journal of Neuroinflammation reported that teriflunomide, an approved multiple sclerosis therapy, ameliorates inflammatory disease by directly inhibiting the NLRP3 inflammasome. The authors reported that NLRP3 inhibition occurs largely independently of teriflunomide’s conventional dihydroorotate dehydrogenase pathway, including direct binding that suppresses NLRP3 ATPase activity. They also linked the mechanism to clinical biomarker changes, including reduced circulating IL-1β in multiple sclerosis patients. The findings broaden the drug’s mechanistic footprint beyond MS and may influence how anti-inflammasome strategies are explored using repurposed compounds.